Summary
Global Markets Direct’s, ‘Poxvirus Infections - Pipeline Review, H1 2016’, provides an overview of the Poxvirus Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Poxvirus Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Poxvirus Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Poxvirus Infections
- The report reviews pipeline therapeutics for Poxvirus Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Poxvirus Infections therapeutics and enlists all their major and minor projects
- The report assesses Poxvirus Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Poxvirus Infections
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Poxvirus Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Poxvirus Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
China Biologic Products, Inc.
SIGA Technologies, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Poxvirus Infections Overview 6
Therapeutics Development 7
Pipeline Products for Poxvirus Infections - Overview 7
Pipeline Products for Poxvirus Infections - Comparative Analysis 8
Poxvirus Infections - Therapeutics under Development by Companies 9
Poxvirus Infections - Therapeutics under Investigation by Universities/Institutes 10
Poxvirus Infections - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Poxvirus Infections - Products under Development by Companies 13
Poxvirus Infections - Products under Investigation by Universities/Institutes 14
Poxvirus Infections - Companies Involved in Therapeutics Development 15
China Biologic Products, Inc. 15
SIGA Technologies, Inc. 16
Poxvirus Infections - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Antibody for Poxvirus Infections - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Monoclonal Antibodies for Infectious Disease - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Small Molecule to Inhibit DNA Synthesis for Poxvirus and Herpes Infections - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
tecovirimat - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
varicella hyperimmune globulins - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Poxvirus Infections - Recent Pipeline Updates 33
Poxvirus Infections - Dormant Projects 36
Poxvirus Infections - Product Development Milestones 37
Featured News & Press Releases 37
Feb 24, 2016: FDA Concurs on Clinical Dose for SIGA’s Tecovirimat Antiviral 37
Mar 12, 2013: Siga Delivers First Courses Of Arestvyr To US Strategic National Stockpile Under BARDA Contract 37
Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 38
Disclaimer 39
List of Tables
Number of Products under Development for Poxvirus Infections, H1 2016 7
Number of Products under Development for Poxvirus Infections - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Poxvirus Infections - Pipeline by China Biologic Products, Inc., H1 2016 15
Poxvirus Infections - Pipeline by SIGA Technologies, Inc., H1 2016 16
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Stage and Target, H1 2016 19
Number of Products by Stage and Mechanism of Action, H1 2016 21
Number of Products by Stage and Route of Administration, H1 2016 23
Number of Products by Stage and Molecule Type, H1 2016 25
Poxvirus Infections Therapeutics - Recent Pipeline Updates, H1 2016 33
Poxvirus Infections - Dormant Projects, H1 2016 36
List of Figures
Number of Products under Development for Poxvirus Infections, H1 2016 7
Number of Products under Development for Poxvirus Infections - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Targets, H1 2016 18
Number of Products by Stage and Targets, H1 2016 18
Number of Products by Mechanism of Actions, H1 2016 20
Number of Products by Stage and Mechanism of Actions, H1 2016 20
Number of Products by Routes of Administration, H1 2016 22
Number of Products by Stage and Routes of Administration, H1 2016 22
Number of Products by Molecule Types, H1 2016 24
Number of Products by Stage and Molecule Types, H1 2016 24
